Abbott Laboratories $ABT Shares Acquired by Astoria Portfolio Advisors LLC.

Astoria Portfolio Advisors LLC. raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,958 shares of the healthcare product maker’s stock after purchasing an additional 113 shares during the period. Astoria Portfolio Advisors LLC.’s holdings in Abbott Laboratories were worth $497,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. Concord Asset Management LLC VA increased its position in shares of Abbott Laboratories by 9.1% during the second quarter. Concord Asset Management LLC VA now owns 13,065 shares of the healthcare product maker’s stock worth $1,777,000 after purchasing an additional 1,087 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Abbott Laboratories by 46.7% during the second quarter. Sequoia Financial Advisors LLC now owns 350,431 shares of the healthcare product maker’s stock worth $47,662,000 after purchasing an additional 111,573 shares in the last quarter. Total Clarity Wealth Management Inc. increased its position in shares of Abbott Laboratories by 22.2% during the second quarter. Total Clarity Wealth Management Inc. now owns 5,281 shares of the healthcare product maker’s stock worth $718,000 after purchasing an additional 959 shares in the last quarter. Vest Financial LLC increased its position in shares of Abbott Laboratories by 12.1% in the 2nd quarter. Vest Financial LLC now owns 592,300 shares of the healthcare product maker’s stock valued at $80,559,000 after acquiring an additional 63,811 shares during the period. Finally, Lion Street Advisors LLC increased its position in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Lion Street Advisors LLC now owns 3,749 shares of the healthcare product maker’s stock valued at $510,000 after acquiring an additional 81 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on ABT. The Goldman Sachs Group upped their target price on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada upped their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and upped their target price for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Leerink Partners began coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price on the stock. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $146.17.

Abbott Laboratories Stock Down 0.8%

ABT opened at $132.30 on Monday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a 50-day moving average price of $132.54 and a 200 day moving average price of $131.60. The company has a market cap of $230.26 billion, a PE ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.